Direct-acting antivirals response in hepatocellular carcinoma: Does the presence of hepatocellular carcinoma matter?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Direct-acting antivirals response in hepatocellular carcinoma: Does the presence of hepatocellular carcinoma matter?

Published:2019-06-25 Issue:2 Volume:25 Page:168-171
ISSN:2287-2728
Container-title:Clinical and Molecular Hepatology
language:en
Short-container-title:Clin Mol Hepatol

Author:

Huang Chung-Feng,Yu Ming-Lung

Funder

Kaohsiung Medical University

Kaohsiung Medical University Hospital

Ministry of Health and Welfare

Publisher

The Korean Association for the Study of the Liver

Subject

Molecular Biology,Hepatology

Link

http://e-cmh.org/upload/pdf/cmh-2018-1014.pdf

Reference19 articles.

1. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level

2. Time-Degenerative Factors and the Risk of Hepatocellular Carcinoma after Antiviral Therapy among Hepatitis C Virus Patients: A Model for Prioritization of Treatment

3. The efficacy and safety of pegylated interferon plus ribavirin combination therapy in chronic hepatitis c patients with hepatocellular carcinoma post curative therapies – A multicenter prospective trial

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Achieving SVR in patients with hepatitis C-related HCC is associated with an improvement in overall survival: real word data;Hepatoma Research;2024-07-11

2. Comparison of the efficacy and safety of direct-acting antiviral therapy with or without hepatitis C-related hepatocellular carcinoma;The Korean Journal of Internal Medicine;2021-03-01

3. Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals;Cancers;2020-11-18

4.

Eradication of Hepatitis C Virus (HCV) Improves Survival of Hepatocellular Carcinoma Patients with Active HCV Infection – A Real-World Cohort Study

;Cancer Management and Research;2020-07

5. Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy;Clinical and Molecular Hepatology;2020-07-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3